<DOC>
	<DOCNO>NCT02853331</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety pembrolizumab ( MK-3475 ) combination axitinib versus sunitinib monotherapy first-line treatment participant advanced/metastatic renal cell carcinoma ( mRCC ) . The primary hypothesis study : 1 ) The combination therapy pembrolizumab plus axitinib superior sunitinib monotherapy respect Progression-Free Survival ( PFS ) assess blinded independent central image review per Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST 1.1 ) 2 ) combination therapy pembrolizumab plus axitinib superior sunitinib monotherapy respect Overall Survival ( OS ) .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Pembrolizumab ( MK-3475 ) Combination With Axitinib Versus Sunitinib Monotherapy Participants With Renal Cell Carcinoma ( MK-3475-426/KEYNOTE-426 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Has histologically confirm diagnosis RCC clear cell component without sarcomatoid feature . Has locally advanced/metastatic disease ( i.e. , newly diagnose Stage IV RCC per American Joint Committee Cancer ) recurrent disease . Has measurable disease per RECIST 1.1 assess investigator/site radiologist . Has receive prior systemic therapy advance RCC . Has provide archival tumor tissue sample newly obtain core excisional biopsy tumor lesion previously irradiate . Has Karnofsky performance status ( KPS ) ≥ 70 % assess within 10 day prior randomization . If receive bone resorptive therapy ( include limit bisphosphonate RANKL inhibitor ) must therapy initiate least 2 week prior randomization . Demonstrates adequate organ function . Female participant childbearing potential must willing use adequate method contraception course study 120 day last dose study drug . Male participant childbearing potential must agree use adequate method contraception , start first dose study drug 120 day last dose study drug . Is currently participate participate study investigational agent use investigational device within 4 week prior randomization . Has major surgery within 4 week , receive radiation therapy within 2 week prior randomization , recover ( i.e. , ≤ Grade 1 baseline ) AEs due prior treatment . Has prior treatment antiprogrammed cell death ( antiPD1 ) , program cell death ligand 1 ( PDL1 ) , PDL2 agent antibody target immuneregulatory receptor mechanism . Has receive prior systemic anticancer therapy RCC vascular endothelial growth factor ( VEGF ) /VEGF receptor ( VEGFR ) mechanistic target rapamycin ( mTOR ) target agent . Has history severe hypersensitivity reaction ( e.g. , generalized rash/erythema , hypotension , bronchospasm , angioedema anaphylaxis ) axitinib sunitinib . Has diagnosis immunodeficiency OR receive systemic steroid therapy exceed physiologic corticosteroid dose form immunosuppressive therapy within 7 day prior randomization , except case central nervous system ( CNS ) metastases . Has active autoimmune disease require systemic treatment past 2 year OR document history clinically severe autoimmune disease . Note : Participants vitiligo , Sjøgren 's syndrome , Type 1 diabetes , resolve childhood asthma/atopy , hypothyroidism adrenal pituitary insufficiency stable hormone replacement , exclude . Has know additional malignancy progress require active treatment last 3 year . Note : Basal cell carcinoma skin , squamous cell carcinoma skin , transitional cell carcinoma urothelial cancer , carcinoma situ breast cancer situ acceptable undergone potentially curative therapy . Has know active CNS metastasis and/or carcinomatous meningitis . Has history ( noninfectious ) pneumonitis require steroid current pneumonitis . Has active infection require systemic therapy . Has know history Human Immunodeficiency Virus ( HIV ) . Has know active Hepatitis B Hepatitis C infection . Has receive live virus vaccine within 30 day randomization . Has clinically significant gastrointestinal ( GI ) abnormality include : Malabsorption , total gastric resection Or condition might affect absorption orally take medication Active GI bleeding , evidence hematemesis , hematochezia melena past 3 month without evidence resolution document endoscopy colonoscopy Intraluminal metastatic lesion suspect bleeding , inflammatory bowel disease , ulcerative colitis GI condition associate increase risk perforation Has QT interval correct heart rate ( QTc ) ≥480 msec . Has history follow cardiovascular condition within 12 month randomization : Myocardial infarction Unstable angina pectoris Cardiac angioplasty stenting Coronary/peripheral artery bypass graft Class III IV congestive heart failure per New York Heart Association Cerebrovascular accident transient ischemic attack Has history deep vein thrombosis pulmonary embolism within 6 month screen . Has poorly control hypertension define systolic blood pressure ( SBP ) ≥150 mm Hg and/or diastolic blood pressure ( DBP ) ≥90 mm Hg . Has evidence inadequate wound heal . Has active bleeding disorder history significant bleeding episode within 30 day randomization . Has hemoptysis within 6 week prior randomization . Has current use ( within 7 day randomization ) anticipate need treatment drug food know strong cytochrome P450 ( CYP3A4/5 ) inhibitor . Has current use ( within 7 day randomization ) anticipate need treatment drug know strong CYP3A4/5 inducer , include limited carbamazepine , phenobarbital , phenytoin , rifabutin , rifampin , St. John 's wort ; drug know proarrhythmic potential . Has know psychiatric substance abuse disorder would interfere cooperation requirement study . Has prior solid organ transplant . Is pregnant breastfeeding , expect conceive father child within project duration study , start screen visit 120 day last dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>VEGFR TKI</keyword>
</DOC>